Shanghai Pharmaceuticals (2607.HK/601607.CH) - Profit Will Resume High Growth in 2024
In 2024, SH Pharma's net profit will resume high growth due to 2023 low base. Interim dividend will be added in 2024. SH Pharma is undervalued and...
372 Views
The Stocks to Own in China – Vol. 35
We highlight 10 stocks in China that look interesting to us based on our FVMR Methodology. Since inception, it has gained 150% versus the CSI 300...
241 Views
The Impact of Trump's Tariffs on China Healthcare - The Victims, And the Safe Haven Assets
As tariff war is heating up, some sectors in China healthcare will be victims, but there will also safe haven assets.The logic behind tariffs is to...
285 Views
Jiangsu Hengrui Pharma A/H Listing - Innovation and Overseas Expansion Driving Earnings Rebound
Jiangsu Hengrui Medicine (600276 CH) a China-based pharmaceutical company, aims to raise around US$2bn in its H-share listing.
396 Views
HUTCHMED to Divest 45% Stake in Non-Core Joint Venture with Shanghai Pharma
HUTCHMED sells 45% stake in SHPL for US$608 million to focus on innovative drug business, which is a right strategic move. If innovative drug...
312 Views